Dietary starch-derived oligosaccharides

Dietary starch-derived oligosaccharides are intermediate carbohydrate molecules, such as maltose, maltotriose, and alpha-limit dextrins, produced during the luminal phase of starch digestion by salivary and pancreatic alpha-amylase (1). These molecules are not therapeutic targets in the classical sense (e.g., receptors or enzymes) but serve as the immediate substrates for the final stage of carbohydrate digestion at the intestinal brush border (2). The enzymes responsible for their hydrolysis into absorbable glucose—specifically maltase-glucoamylase and sucrase-isomaltase—are the actual pharmacological targets for managing glycemic levels (3). By inhibiting these enzymes, drugs like acarbose and miglitol prevent the rapid breakdown of these oligosaccharides, thereby slowing the rate of glucose absorption into the bloodstream (4). This mechanism is particularly useful in treating type 2 diabetes mellitus to reduce postprandial hyperglycemia (5). However, the presence of undigested oligosaccharides in the distal small intestine and colon can lead to osmotic effects and bacterial fermentation, resulting in common gastrointestinal side effects (6). Citations: (1) PubMed: PMC3823506; (2) StatPearls: Alpha-Glucosidase Inhibitors; (3) PubChem: Acarbose; (4) NIH: Carbohydrate Metabolism; (5) Mayo Clinic: Type 2 Diabetes Treatment; (6) Journal of Clinical Medicine: Side effects of AGIs.

Other names

MaltodextrinsAlpha-limit dextrinsMalto-oligosaccharidesStarch hydrolysis productsMaltose and maltotriose

Competitive inhibition of brush-border alpha-glucosidase enzymes to prevent the hydrolysis of oligosaccharides into glucose.